Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity

Background: Published trials of concurrent chemoradiotherapy (CCRT) in stage III non-small-cell lung cancer (NSCLC) generally excluded patients with significant comorbidity. We evaluated outcomes in patients who were selected by using radiation planning parameters and were considered, despite comorb...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2011-01, Vol.22 (1), p.132-138
Hauptverfasser:	Phernambucq, E.C.J., Spoelstra, F.O.B., Verbakel, W.F.A.R., Postmus, P.E., Melissant, C.F., Maassen van den Brink, K.I., Frings, V., van de Ven, P.M., Smit, E.F., Senan, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - radiotherapy Charlson comorbidity index Cisplatin - administration & dosage Combined Modality Therapy Comorbidity concurrent chemoradiotherapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Etoposide - administration & dosage Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - radiotherapy Male Medical sciences Middle Aged Neoplasm Staging patient selection Pharmacology. Drug treatments Pneumology stage III NSCLC Survival Rate toxicity Treatment Outcome Tumors of the respiratory system and mediastinum
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background: Published trials of concurrent chemoradiotherapy (CCRT) in stage III non-small-cell lung cancer (NSCLC) generally excluded patients with significant comorbidity. We evaluated outcomes in patients who were selected by using radiation planning parameters and were considered, despite comorbidity, fit enough to receive cisplatin-based chemotherapy. Patients and methods: From 2003 to 2008, 89 patients with stage III NSCLC fit to receive cisplatin-based chemotherapy and a V20
ISSN:	0923-7534 1569-8041
DOI:	10.1093/annonc/mdq316